Description

Gefitinib Tablets: A Targeted Therapy for Non-Small Cell Lung Cancer

Product Name: Gefitinib Tablets

Indication: Gefitinib is a targeted therapy indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) mutations. This includes patients with exon 19 deletions or exon 21 (L858R) substitutions in the EGFR gene. It is crucial to confirm the presence of these mutations via a validated testing method before initiating treatment.

Mechanism of Action: Gefitinib is an EGFR tyrosine kinase inhibitor (TKI). It works by selectively binding to the EGFR tyrosine kinase domain, preventing the activation of the receptor and inhibiting downstream signaling pathways crucial for tumor cell growth and survival. By blocking the EGFR pathway, Gefitinib slows or stops the growth of cancer cells that depend on this signaling pathway for proliferation.

Dosage and Administration:

• Dosage: The recommended starting dose is typically 250 mg once daily orally. Dosage adjustments may be necessary based on individual patient tolerance and response.
• Administration: Gefitinib tablets should be swallowed whole with water. They should be taken at approximately the same time each day.
• Note: Dosage and administration instructions should always be followed as prescribed by a healthcare professional. This description is for informational purposes only and does not constitute medical advice.

Contraindications: Gefitinib is contraindicated in patients with known hypersensitivity to Gefitinib or any of its components.

Warnings and Precautions:

• Interstitial Lung Disease (ILD): Gefitinib can cause ILD, a potentially fatal condition. Patients should be monitored closely for symptoms such as cough, shortness of breath, and decreased lung function. Treatment should be discontinued immediately if ILD is suspected.
• Diarrhea: Diarrhea is a common side effect of Gefitinib and can be severe. Patients should be advised on managing diarrhea and seek medical attention if it becomes severe or persistent.
• Skin Rash: Skin rash is another common side effect. While usually mild, severe rash may require dose reduction or treatment discontinuation.
• Hepatotoxicity: Elevated liver enzymes have been reported. Liver function tests should be monitored regularly.
• Drug Interactions: Gefitinib may interact with other medications. Patients should inform their healthcare provider of all medications, including over-the-counter drugs and herbal supplements.
• Pregnancy and Breastfeeding: Gefitinib is contraindicated in pregnant women and women who are breastfeeding. Effective contraception should be used during treatment.

Adverse Reactions: Common adverse reactions include diarrhea, rash, nausea, vomiting, fatigue, anorexia, and increased liver enzymes. More serious adverse reactions, including ILD, can also occur. The complete list of adverse reactions can be found in the full prescribing information.

Storage: Store Gefitinib tablets at controlled room temperature (20°C to 25°C) in a tightly closed container. Protect from moisture and light.

Disclaimer: This information is intended for educational purposes only and should not be considered medical advice. Always consult with a healthcare professional before starting or changing any medication. Always refer to the official prescribing information for complete details regarding indications, contraindications, warnings, precautions, adverse reactions, and dosage. The information provided here is not exhaustive and may not include all potential side effects or interactions.